Tiziana Life Sciences Ltd (TLSA NASDAQ) stock market data APIs
$1.9272
-0.03(-1.6%)
as of October 24, 2025
Try our APIs with
free plan!
Tiziana Life Sciences Ltd Financial Data Overview
Price chart is built with
Anychart
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Prev. Close
1.9272
Open
1.9008
High
1.9591
Low
1.8796
52 wk Range
0.6295-2.6
Market Cap
231 M
Shares Outstanding
119 M
Revenue
-3 595 000
Beta
0.242
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tiziana Life Sciences Ltd data using free add-ons & libraries
Get Tiziana Life Sciences Ltd Fundamental Data
Tiziana Life Sciences Ltd Fundamental data includes:
- Net Revenue: -3 595 000
- EBITDA: -18 464 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tiziana Life Sciences Ltd News
New
Tesla Investors Should Reject Musk Pay Package, Glass Lewis Says
Glass Lewis, which makes recommendations to investors about how they should vote on company proposals, has joined Institutional Shareholder Services in suggesting that Tesla shareholders reject Musk’s proposed $1 trillion compensation plan. Continue Reading View Comments
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
Tiziana Life Sciences Ltd. BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset...
Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Tiziana Life Sciences Ltd is one of them. Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-s...
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
